Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004,...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of WVE is 21 and suggests 56% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell